Due to health issues, this site is no longer maintained and will be shut down shortly.

NO:NANOV Nordic Nanovector As

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company's lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.

0.90 NOK
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Norway
Country of incorporation:  Norway
IPO date:  07/08/2014
Stock exchange:    Oslo Bors Asa
Exchange country:   Norway
Market cap:   1,361,090,560 NOK
Current dividend yield:   0.00%
Sedol:      BJ0ZN64

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy